Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands.

[1]  Toshiyuki Shimizu,et al.  Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. , 2016, Immunity.

[2]  A. Mansell,et al.  Toll-like receptors: the swiss army knife of immunity and vaccine development , 2016, Clinical & translational immunology.

[3]  K. Ishii,et al.  Vaccine adjuvants as potential cancer immunotherapeutics , 2016, International immunology.

[4]  Huimin Yan,et al.  Targeting C-Type Lectin Receptors for Cancer Immunity , 2015, Front. Immunol..

[5]  Shiyin Yao,et al.  Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. , 2015, Bioconjugate chemistry.

[6]  Janine K. Tom,et al.  Directing the immune system with chemical compounds. , 2014, ACS chemical biology.

[7]  E. Davila,et al.  TLR agonists: our best frenemy in cancer immunotherapy , 2013, Journal of leukocyte biology.

[8]  L. Zitvogel,et al.  Trial watch , 2012, Oncoimmunology.

[9]  T. Mcinally,et al.  Biological characterization of a novel class of toll‐like receptor 7 agonists designed to have reduced systemic activity , 2012, British journal of pharmacology.

[10]  P. Massari,et al.  The Role of TLR2 in Infection and Immunity , 2012, Front. Immun..

[11]  F. Osorio,et al.  Myeloid C-type lectin receptors in pathogen recognition and host defense. , 2011, Immunity.

[12]  Yanmei Zhang,et al.  Synthesis and characterization of PEGylated toll like receptor 7 ligands. , 2011, Bioconjugate chemistry.

[13]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[14]  Tomoaki Nakamura,et al.  Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept. , 2010, Journal of medicinal chemistry.

[15]  H. Cottam,et al.  Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates , 2009, Bioconjugate chemistry.

[16]  Pengfei Zhang,et al.  Synthesis of Novel Schiff Bases from the Reaction of 3-O-methyl-4, 6-O-benzylidene-β-D-glucopyranosylamine with substituted aldehydes , 2009 .

[17]  S. Ng,et al.  Facile synthesis of mono-6-amino-6-deoxy-α-, β-, γ-cyclodextrin hydrochlorides for molecular recognition, chiral separation and drug delivery , 2008, Nature Protocols.

[18]  D. Smee,et al.  Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand , 2007, Proceedings of the National Academy of Sciences.

[19]  Shizuo Akira,et al.  Antiviral signaling through pattern recognition receptors. , 2006, Journal of biochemistry.

[20]  H. Cottam,et al.  Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists. , 2006, Bioorganic & medicinal chemistry letters.

[21]  D. Agrawal,et al.  Immunobiology of Toll‐like receptors: Emerging trends , 2006, Immunology and cell biology.

[22]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[23]  M. Gunzer,et al.  incompetence due to peripheral blood leukocyte depletion Systemic administration of a TLR7 ligand leads to transient immune , 2013 .

[24]  Samuel I. Miller,et al.  LPS, TLR4 and infectious disease diversity , 2005, Nature Reviews Microbiology.

[25]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[26]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[27]  A. Kurimoto,et al.  Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. , 2004, Bioorganic & medicinal chemistry.

[28]  Jongdae Lee,et al.  Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[30]  G. Kinghorn,et al.  Imiquimod and resiquimod as novel immunomodulators. , 2001, The Journal of antimicrobial chemotherapy.

[31]  D. Cooper,et al.  Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. , 1998, The Journal of infectious diseases.

[32]  M. Gore,et al.  A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. , 1996, British Journal of Cancer.

[33]  Roger Mayer,et al.  Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes , 1994 .

[34]  G. Batta,et al.  Synthesis of the Anomers of Hepta-O-acetylcellobiosyl, -lactosyl, - maltosyl, and -melibiosyl Azide. , 1991 .

[35]  H. Isbell,et al.  Mutarotation, Hydrolysis, and Rearrangement Reactions of Glycosylamines1 , 1958 .